Are Lymphokine Activated Killer Cells a Possible Form of Leukaemia Immunotherapy?
- 1 January 1988
- book chapter
- Published by Springer Nature
- Vol. 237, 447-450
- https://doi.org/10.1007/978-1-4684-5535-9_68
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant gliomaJournal of Neurosurgery, 1986
- Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.The Journal of Immunology, 1985
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB studyBlood, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Activation of Human Natural Killer Cells Cytotoxic for Human Leukemia Cells by Purified InterferonThe Journal of Immunology, 1979
- K562—A human erythroleukemic cell lineInternational Journal of Cancer, 1979
- Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)International Journal of Cancer, 1976